Ensysce Biosciences Inc (ENSC) - Total Liabilities
Based on the latest financial reports, Ensysce Biosciences Inc (ENSC) has total liabilities worth $2.84 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Ensysce Biosciences Inc to track the company's year-over-year net asset growth rate.
Ensysce Biosciences Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Ensysce Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. See Ensysce Biosciences Inc (ENSC) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Ensysce Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Ensysce Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NFT Limited
NYSE MKT:MI
|
USA | $6.18 Million |
|
Classic Minerals Ltd
AU:CLZ
|
Australia | AU$29.77 Million |
|
Canasil Resources Inc.
V:CLZ
|
Canada | CA$522.09K |
|
Svenska Aerogel Holding AB (publ)
ST:AERO
|
Sweden | Skr6.98 Million |
|
Groupe Airwell Société anonyme
PA:ALAIR
|
France | €35.54 Million |
|
Cooper Metals Ltd
AU:CPM
|
Australia | AU$58.06K |
|
Aeon Metals Ltd
AU:AML
|
Australia | AU$40.24 Million |
|
Rokeby Resources Limited
AU:RKB
|
Australia | AU$360.20K |
Liability Composition Analysis (2017–2025)
This chart breaks down Ensysce Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Ensysce Biosciences Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -8.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ensysce Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ensysce Biosciences Inc (2017–2025)
The table below shows the annual total liabilities of Ensysce Biosciences Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.57 Million | +106.00% |
| 2024-12-31 | $2.22 Million | -34.00% |
| 2023-12-31 | $3.36 Million | -66.12% |
| 2022-12-31 | $9.91 Million | -59.66% |
| 2021-12-31 | $24.58 Million | +250.56% |
| 2020-12-31 | $7.01 Million | -32.19% |
| 2019-12-31 | $10.34 Million | +38.95% |
| 2018-12-31 | $7.44 Million | +3.96% |
| 2017-12-31 | $7.16 Million | -- |
About Ensysce Biosciences Inc
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR)… Read more